These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24441505)

  • 1. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.
    Huen AO; Rook AH
    Curr Opin Oncol; 2014 Mar; 26(2):237-44. PubMed ID: 24441505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod.
    Spaner DE; Miller RL; Mena J; Grossman L; Sorrenti V; Shi Y
    Leuk Lymphoma; 2005 Jun; 46(6):935-9. PubMed ID: 16019542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine, cytokine and type I interferon production induced by Toll-like receptor activation in common variable immune deficiency.
    Lollo C; de Moraes Vasconcelos D; Oliveira LMDS; Domingues R; Carvalho GC; Duarte AJDS; Sato MN
    Clin Immunol; 2016 Aug; 169():121-127. PubMed ID: 27392462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo cancer vaccination: Which dendritic cells to target and how?
    Chiang CL; Kandalaft LE
    Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
    Kim YH; Girardi M; Duvic M; Kuzel T; Link BK; Pinter-Brown L; Rook AH
    J Am Acad Dermatol; 2010 Dec; 63(6):975-83. PubMed ID: 20888065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Immunosuppressive Effects of CpG-c41 on Intracellular TLR-Mediated Inflammation.
    Liu W; Yang X; Wang N; Fan S; Zhu Y; Zheng X; Li Y
    Mediators Inflamm; 2017; 2017():6541729. PubMed ID: 28539706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 7 agonists and skin.
    Novak N; Yu CF; Bieber T; Allam JP
    Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
    Wysocka M; Newton S; Benoit BM; Introcaso C; Hancock AS; Chehimi J; Richardson SK; Gelfand JM; Montaner LJ; Rook AH
    Clin Lymphoma Myeloma; 2007 Sep; 7(8):524-34. PubMed ID: 18021470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses.
    Yang K; Puel A; Zhang S; Eidenschenk C; Ku CL; Casrouge A; Picard C; von Bernuth H; Senechal B; Plancoulaine S; Al-Hajjar S; Al-Ghonaium A; Maródi L; Davidson D; Speert D; Roifman C; Garty BZ; Ozinsky A; Barrat FJ; Coffman RL; Miller RL; Li X; Lebon P; Rodriguez-Gallego C; Chapel H; Geissmann F; Jouanguy E; Casanova JL
    Immunity; 2005 Nov; 23(5):465-78. PubMed ID: 16286015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic agonists of Toll-like receptors 7, 8 and 9.
    Agrawal S; Kandimalla ER
    Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
    Lai CY; Su YW; Lin KI; Hsu LC; Chuang TH
    J Immunol Res; 2017; 2017():7807313. PubMed ID: 28894754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR activation pathways in HIV-1-exposed seronegative individuals.
    Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
    J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR expression in human melanoma cells.
    Saint-Jean M; Knol AC; Nguyen JM; Khammari A; Dréno B
    Eur J Dermatol; 2011; 21(6):899-905. PubMed ID: 21926036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects.
    Wenzel J; Tormo D; Tüting T
    Handb Exp Pharmacol; 2008; (183):201-20. PubMed ID: 18071661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptors and genital tract infection.
    Sonnex C
    Int J STD AIDS; 2010 Mar; 21(3):153-7. PubMed ID: 20215617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.
    Kuznik A; Bencina M; Svajger U; Jeras M; Rozman B; Jerala R
    J Immunol; 2011 Apr; 186(8):4794-804. PubMed ID: 21398612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.